{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&_metadata=all&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&AnsweringBody.=Department+of+Health+and+Social+Care&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?AnsweringBody.=Department+of+Health+and+Social+Care&answer.previousAnswerVersion.answeringMember.label=Biography+information+for+Maria+Caulfield", "items" : [{"_about" : "http://data.parliament.uk/resources/1718234", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1718234/answer", "answerText" : {"_value" : "
All routine policy, including the Vaccine Damage Payment Scheme (VDPS), is reviewed on a regular basis. My Rt hon. Friend, the Secretary of State for Health and Social Care is currently looking into aspects of the scheme, following recent meetings with interested stakeholders.<\/p>
Separately, work is underway with the scheme\u2019s administrator, the NHS Business Service Authority, to review processes and make administrative changes, to improve the scheme within the current legislative framework. Formal consideration of whether any reforms to the VDPS are necessary will form part of Module 4 of the COVID-19 Inquiry, chaired by the Rt Hon Baroness Heather Carol Hallett DBE.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} , "dateOfAnswer" : {"_value" : "2024-05-22", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "26628"} , {"_value" : "26635"} , {"_value" : "26636"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1718234/answer/previousversion/35275", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} } , "questionFirstAnswered" : [{"_value" : "2024-05-22T10:43:11.323Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-15", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Vaccine Damage Payment Scheme: Reviews"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what the terms of reference are for her Department's review of the vaccine damage compensation scheme; which body is responsible for undertaking the review; and what estimate she has made of when the review will be completed.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"} } , "tablingMemberConstituency" : {"_value" : "Christchurch"} , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"} ], "uin" : "26322"} , {"_about" : "http://data.parliament.uk/resources/1715634", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1715634/answer", "answerText" : {"_value" : "
The Department has not directly received data from AstraZeneca regarding potential adverse effects of their COVID-19 vaccine Vaxzevria, as it is not the appropriate body to receive this information. It instead relies on the expert advice of the Medicines and Healthcare products Regulatory Agency (MHRA).<\/p>
All vaccine manufacturers have a legal responsibility to mitigate risk and monitor the safety and performance of vaccines throughout the product lifecycle. This includes a legal responsibility to transmit reports of suspected adverse reactions received directly to the MHRA. Following the MHRA\u2019s receipt of the first Yellow Card reports of suspected thrombosis and associated thrombocytopaenia associated with the Vaxzevria vaccine in February 2021, AstraZeneca provided the Commission on Human Medicines\u2019 Vaccine Benefit Risk Expert Working Group an analysis of the age stratified risk of thrombosis with thrombocytopenia associated with the AstraZeneca vaccine. This was assessed by the Commission on Human Medicines, with the Patient Information updated to state the risks of these events.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} , "dateOfAnswer" : {"_value" : "2024-05-15", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1715634/answer/previousversion/32814", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} } , "questionFirstAnswered" : [{"_value" : "2024-05-15T10:08:51.197Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-05-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Coronavirus: Vaccination"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, whether (a) his Department and (b) the Medicines and Healthcare products Regulatory Agency has received data from Astra Zeneca on the potential serious adverse effects of its covid-19 vaccine for a small number of recipients.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/242", "label" : {"_value" : "Biography information for Sir Christopher Chope"} } , "tablingMemberConstituency" : {"_value" : "Christchurch"} , "tablingMemberPrinted" : [{"_value" : "Sir Christopher Chope"} ], "uin" : "24607"} , {"_about" : "http://data.parliament.uk/resources/1714863", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714863/answer", "answerText" : {"_value" : "
The Department has had no such discussions with Elysium Healthcare, individual National Health Service commissioning organisations hold contracts with NHS and non-NHS providers for specified services, as part of their commissioning function. NHS England has advised that NHS Cheshire and Merseyside Integrated Care Board (ICB) contracts with Elysium Healthcare under spot purchase agreements, which means that a contract is only ongoing for the duration of an individual patient\u2019s placement.<\/p>
The ICB continues to work with St Mary's Hospital in Warrington, part of the Elysium Healthcare Group. Quality visits have taken place at the St Mary\u2019s Hospital estate, alongside visits by the NHS England Specialised Commissioning team, and Care Quality Commission (CQC) visits. All contracts with non-NHS providers are subject to NHS contract quality reviews, in addition to the regulatory regime of the CQC.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} , "dateOfAnswer" : {"_value" : "2024-05-13", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "previousAnswerVersion" : {"_about" : "http://data.parliament.uk/resources/1714863/answer/previousversion/32561", "answeringMember" : {"_about" : "http://data.parliament.uk/members/4492", "label" : {"_value" : "Biography information for Maria Caulfield"} } , "answeringMemberConstituency" : {"_value" : "Lewes"} , "answeringMemberPrinted" : {"_value" : "Maria Caulfield"} } , "questionFirstAnswered" : [{"_value" : "2024-05-13T11:04:02.427Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-04-30", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Elysium Healthcare: Contracts"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what discussions her Department has had with Elysium Healthcare on continuing its contract following the inquest into the death of Liam McGenity.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/429", "label" : {"_value" : "Biography information for Derek Twigg"} } , "tablingMemberConstituency" : {"_value" : "Halton"} , "tablingMemberPrinted" : [{"_value" : "Derek Twigg"} ], "uin" : "24189"} , {"_about" : "http://data.parliament.uk/resources/1714096", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1714096/answer", "answerText" : {"_value" : "
No specific assessment has been made. We are investing £25 million in women\u2019s health hubs, so that women can get better access to care for menstrual problems, contraception, menopause, and more. Integrated care boards (ICBs) are responsible for commissioning services that meet the needs of their local population, and will determine the exact services that their women\u2019s health hub will provide, so long as they deliver the core services set out in the Women\u2019s Health Hubs: Core Specification, which is available at the following link:<\/p>
<\/p><\/td> | Learning disability<\/p><\/td> | Autism services<\/p><\/td> | Unseparated learning disability and autism services<\/p><\/td> | Total<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||
2019/20<\/p><\/td> | N/A<\/p><\/td> | N/A<\/p><\/td> | £1,809,200,000<\/p><\/td> | £1,809,200,000<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||
2020/21<\/p><\/td> | N/A<\/p><\/td> | N/A<\/p><\/td> | £2,285,600,000<\/p><\/td> | £2,285,600,000<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||
2021/22<\/p><\/td> | £85,800,000<\/p><\/td> | £3,700,000<\/p><\/td> | £2,268,300,000<\/p><\/td> | £2,357,900,000<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||
2022/23<\/p><\/td> | £625,800,000<\/p><\/td> | £27,100,000<\/p><\/td> | £1,928,800,000<\/p><\/td> | £2,581,700,000<\/p><\/td><\/tr> | ||||||||||||||||||||||||||||||||||||||||||||||||||||
2023/24<\/p><\/td> | £926,000,000<\/p><\/td> | £47,100,000<\/p><\/td> | £1,928,800,000<\/p><\/td> | £2,904,600,000<\/p><\/td><\/tr><\/tbody><\/table> <\/p> In addition, specific funding has been allocated to ICBs in 2023/4 and 2024/25 from the Service Development Funding, to improve autism assessment waiting lists and pathways. The following table shows information on the additional national funding allocated to ICBs by NHS England, over each of the last five years, to improve autism assessment waiting lists and pathways:<\/p>
|